{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:30:53Z","timestamp":1788546653372,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.lungcan.2023.107346","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T20:51:37Z","timestamp":1692219097000},"page":"107346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Efficacy and safety of re-challenging 160\u00a0mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study"],"prefix":"10.1016","volume":"184","author":[{"given":"Rongbin","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-9596","authenticated-orcid":false,"given":"Dongqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2023.107346_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107346_b0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"14","key":"10.1016\/j.lungcan.2023.107346_b0015","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.107346_b0020","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2023.107346_b0025","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107346_b0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1759-7714.13255","article-title":"Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation","volume":"11","author":"Hayakawa","year":"2020","journal-title":"Thorac Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2023.107346_b0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107346_b0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107346_b0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China. A Randomized Study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol."},{"issue":"27","key":"10.1016\/j.lungcan.2023.107346_b0050","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107346_b0055","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107346_b0060","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/cancers15030841","article-title":"Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options","volume":"15","author":"Gomatou","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.lungcan.2023.107346_b0065","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/CAD.0000000000001368","article-title":"Successful salvage therapy using high-dose furmonertinib (AST2818) for non-small-cell lung cancer after Osimertinib resistance: a case report","volume":"33","author":"Cheng","year":"2022","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107346_b0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation","volume":"15","author":"Shi","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107346_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-02865-z","article-title":"Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies","volume":"21","author":"Hu","year":"2023","journal-title":"BMC Med."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107346_b0080","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107346_b0085","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107346_b0090","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107346_b0095","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jtho.2017.06.017","article-title":"Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance","volume":"12","author":"Wang","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107346_b0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107346_b0105","article-title":"Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107346_b0110","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10467-w","article-title":"Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial","volume":"23","author":"Miura","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2023.107346_b0115","series-title":"Furmonertinib is an Oral, Irreversible, Highly Brain-Penetrant Pan-EGFR Mutant Inhibitor with Activity Against Classical and Atypical EGFR Mutations","author":"Luna Musib","year":"2023"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300884X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300884X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:59Z","timestamp":1759237559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022300884X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":23,"alternative-id":["S016950022300884X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107346","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of re-challenging 160\u00a0mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107346"}}